When Novartis announced plans to hand off its consumer health operations to a joint venture with GlaxoSmithKline, the companies said they figured they could save a boatload of money in "synergies." It looks like a small part of that will come from closing a Novartis plant in Puerto Rico that makes consumer and veterinary products, shedding 270 jobs in the process.
The deal gives Novartis access to the most active digital health VC team--Rock Health reports Qualcomm Ventures has struck 21 deals since 2011--and further strengthens the ties between the two companies.
Novartis, in the midst of a long-running effort to make clinical trials more efficient, has recruited Qualcomm to help it gather and store patient data from medical devices.
At San Francisco's giant JP Morgan Healthcare Conference, tech company Qualcomm and Big Pharma player Novartis revealed a plan for a joint investment company with $100 million to spend on startups that "go beyond the pill."
Novartis has added another component to its "Clinical Trials of the Future" program. The latest element of the trial efficiency initiative sees the Swiss Big Pharma team up with computer chip maker Qualcomm to gather data on clinical trial participants between visits to the investigator site.
U.K. officials have decided which drugs to toss off the Cancer Drug Fund, which pays for drugs rejected by cost-effectiveness gatekeepers. Reportedly, Novartis, Sanofi and Eisai treatments are among them.
A group of FDA advisers unanimously recommended approval for Novartis' knockoff of a blockbuster Amgen treatment, clearing the way for what would be the first U.S. approval of a copycat biologic medicine.
Novartis claims its Theraflu Multi-Symptom Severe Cold "starts to get to work in your body in 5 minutes" after taking it. But Pfizer, which sells its own range of cold-fighters, has an issue with that--and so does National Advertising Division.
Novartis claims its Theraflu Multi-Symptom Severe Cold "starts to get to work in your body in 5 minutes" after taking it. But competitor Pfizer isn't having it--and neither is the National Advertising Division.
Just weeks after Novartis and Atlas Venture announced the launch of an upstart player in the fast-emerging field of CRISPR-Cas9 gene editing, the pharma giant has stepped back up to formally hammer out a partnership development deal and throw its enormous resources behind the biotech.